Lakewood-Amedex Biotherapeutics
LABT
Positions held
Your positionsLABT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $1.88M | Enterprise value | -$2.61M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.40 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -4.0% | ROA | -139.4% | Debt / equity | 0.02 |
| Current ratio | 7.70 | Free cash flow | -$911,355 | Analyst recommendation | strong_buy | Mean target | $12.00 |
| 52w high | $98.20 | 52w low | $0.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.8M | -$0.9M | -$0.7M | -$1.9M | -$0.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.8M | -$0.9M | -$0.7M | -$1.9M | -$0.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — |
| Net income | -$3.8M | -$4.9M | -$8.3M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$3.8M | -$4.0M | -$8.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences
2026-09-28 · Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates
2026-09-28 · LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-24 · Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
2026-09-08 · Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-26 · LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers
2026-08-25 · Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company
Price (daily)
Full chart · RSI · MACD · patterns